LONDON , Sept. 12,
2024 /PRNewswire/ -- Cizzle Biotechnology Holdings
plc ("Cizzle"), a UK-based diagnostics company specialising in
early-stage lung cancer detection, announces a pivotal
collaboration with Moffitt Cancer Center, Florida's leading cancer hospital. This
partnership will clinically evaluate Cizzle's proprietary CIZ1B
biomarker assay in patients with suspicious lung nodules, marking a
significant step in the fight to reduce the number of deaths from
lung cancer by using a simple blood test instead of the current
costly, time consuming and invasive process.
Key Highlights:
- Partnership with Moffitt Cancer Center: As the only US
National Cancer Institute-designated 'Comprehensive Cancer Center'
in Florida, Moffitt is renowned
for its top-tier lung cancer screening and research programs.
- First-ever clinical evaluation: The study will test patients
with indeterminate lung nodules for the CIZ1B biomarker,
potentially providing more accurate early-stage lung cancer
detection.
- Cutting-edge technology: The evaluation will
utilize Cizzle's newly developed monoclonal antibodies,
produced in collaboration with BBI Solutions.
- Blood sample analysis at the University of York: Samples
from Moffitt's patients will be analysed at the laboratory
where the CIZ1B biomarker was first developed.
A Pioneering Study:
This collaboration is part of Moffitt's Phase 2 program, "Using
Biomarkers for Diagnosis, Risk Stratification of Post-treatment
Recurrence and Long-Term Survival of Lung Cancer." Led by Dr. Lary
Robinson, Director of Moffitt's Lung Cancer Early Detection Center,
the study will evaluate Cizzle's CIZ1B biomarker's ability to
detect lung cancer early, aiming to reduce false positives and
unnecessary interventions caused by CT scans.
Strategic US Expansion:
The partnership with Moffitt arose from the early progress
of Cizzle's US-based partner, Cizzle Bio Inc., which brings an
experienced team of healthcare professionals and clinicians to
drive the business forward in North
America. The Moffitt study will be important in
demonstrating the value of a simple blood-based biomarker test in
early lung cancer detection.
A Global Opportunity to Save Lives:
With lung cancer claiming nearly 5,000 lives daily worldwide,
early detection is crucial. Cizzle's CIZ1B biomarker blood
test offers a cost-effective, non-invasive solution to detect lung
cancer in its earliest stages, potentially saving lives and
reducing healthcare burdens.
Allan Syms, Executive Chairman
of Cizzle Biotechnology, commented:
"Our collaboration with Moffitt Cancer Center is a
transformative moment for Cizzle. Moffitt's reputation as one of
the largest and most respected cancer centers in the U.S. makes
this partnership a significant milestone in advancing our CIZ1B
biomarker test. For the first time, patients with suspicious lung
nodules at a major cancer clinic will be evaluated using our test
as part of their clinical assessment.
This collaboration highlights the potential of our biomarker to
reduce false positives from CT scans, offering clinicians a
powerful tool to better identify patients at risk for early-stage
lung cancer as well as future screening and surveillance.
With Moffitt's leadership in lung cancer research and
screening, we are excited to bring this innovative test to all
patients."
For more details, visit Cizzle Biotechnology.
Contact - allan@cizzlebiotech.com
View original
content:https://www.prnewswire.co.uk/news-releases/cizzle-biotechnology-announces-groundbreaking-collaboration-with-moffitt-cancer-center-to-advance-early-stage-lung-cancer-detection-302246491.html